Immunosuppression After Liver Transplantation for Primary Sclerosing Cholangitis Influences Activity of Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 5, 2013, Pages 517-523

  Jørgensen, Kristin Kaasen ^a,b   Lindström, Lina ^c   Cvancarova, Milada ^b   Karlsen, Tom H ^a,d   Castedal, Maria ^e   Friman, Styrbjörn ^e   Schrumpf, Erik ^a,b   Foss, Aksel ^a,b   Isoniemi, Helena ^f   Nordin, Arno ^f   Holte, Kathrine ^g   Rasmussen, Allan ^g   Bergquist, Annika ^c   Vatn, Morten H ^a,b,h   Boberg, Kirsten Muri ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BERGEN   (Norway)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g Rigshospitalet   (Denmark)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Colitis; Crohn's Disease; Disease Progression; Therapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLON RESECTION; COLONOSCOPY; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER PROTECTION; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREOPERATIVE CARE; PRESCHOOL CHILD; PRIMARY SCLEROSING CHOLANGITIS; RECURRENCE RISK; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; CHOLANGITIS, SCLEROSING; COLON; COLONOSCOPY; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84876734631     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.027     Document Type: Article

References (31)

1. Karlsen T.H. Annual report 2010 The Nordic Liver Transplant Registry (NLTR). http://www.scandiatransplant.org.
2. Wiesner R.H., Grambsch P.M., Dickson E.R., et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989, 10:430-436.
3. Fausa O., Schrumpf E., Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991, 11:31-39.
4. Jørgensen K.K., Grzyb K., Lundin K.E., et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and nontransplanted patients. Inflamm Bowel Dis 2012, 18:536-545.
5. Loftus E.V., Harewood G.C., Loftus C.G., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
6. Joo M., Abreu-e-Lima P., Farraye F., et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009, 33:854-862.
7. Lundqvist K., Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997, 40:451-456.
8. Soetikno R.M., Lin O.S., Heidenreich P.A., et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
9. Broomé U., Löfberg R., Veress B., et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404-1408.
10. Broomé U., Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006, 26:31-41.
11. Loftus E.V., Aguilar H.I., Sandborn W.J., et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998, 27:685-690.
12. Gavaler J.S., Delemos B., Belle S.H., et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991, 36:321-328.
13. Saldeen K., Friman S., Olausson M., et al. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999, 34:535-540.
14. van de Vrie W., de Man R.A., van Buuren H.R., et al. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003, 15:657-663.
15. Dvorchik I., Subotin M., Demetris A.J., et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002, 35:380-384.
16. Haagsma E.B., Van den Berg A.P., Kleibeuker J.H., et al. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003, 18:33-44.
17. Moncrief K.J., Savu A., Ma M.M., et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation-a single-centre experience. Can J Gastroenterol 2010, 24:40-46.
18. Verdonk R.C., Dijkstra G., Haagsma E.B., et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006, 6:1422-1429.
19. Chapman R.W., Arborgh B.A., Rhodes J.M., et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980, 21:870-877.
20. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
21. Ho G.T., Seddon A.J., Therapondos G., et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005, 17:1379-1385.
22. Riis L., Vind I., Politi P., et al. Does pregnancy change the disease course?. A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:1539-1545.
23. Henriksen M., Jahnsen J., Lygren I., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006, 12:543-550.
24. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
25. Pintilie M., Risks C. A practical perspective 2006, John Wiley & Sons, Chichester, UK.
26. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.
27. Ng S.C., Chan F.K., Sung J.J. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:417-427.
28. Stephens J., Goldstein R., Crippin J., et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993, 25:1122-1123.
29. Joshi D., Bjarnason I., Belgaumkar A., et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013, 33:53-61.
30. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
31. Scott L.J., McKeage K., Keam S.J., et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63:1247-1297.